Intensity Therapeutics reports Q2 2023 results; IPO nets $20.5M, INT230-6 shows survival benefit in sarcoma

INTENSITY THERAPEUTICS, INC.

2023-Q2 EPS reported -$1.45

Closed upsized IPO of 3.9M shares at $5.00/sh, net proceeds $20.5M; cash runway extended into early Q3 2025.
INT230-6 data at ASCO: median OS 21.3 months in refractory metastatic sarcoma vs historical 7-10 months.
Net operating loss $1.2M in Q2 2023 vs $1.9M in Q2 2022; non-operating loss $2.3M from convertible debt discount included.
Plan to file IND for phase 3 study of INT230-6 in soft tissue sarcoma by end of 2023.
Additional INVINCIBLE breast cancer data expected by year-end; phase 2/3 program planned.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTENSITY THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: net income Net Operating Loss for the second quarter ended June 30, 2023 was $1.2 million.

Period: second quarter ended June 30, 2023
Net income: Net Operating Loss for the second quarter ended June 30, 2023 was $1.2 million
Result: reported results

Exact text from the filing

Intensity Therapeutics, Inc. (the “ Company ”) released its financial results for the quarter ended June 30, 2023. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

INTENSITY THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-066456

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.